Dr. Songhui xu, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi, China, China
Dr. Song-Hui Xu is an accomplished Associate Professor in the Department of Urology at The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, China. Born in 1984, he has emerged as a leading researcher in cancer biology, particularly prostate and bladder cancershttps://cellbiologist.org/songhui-xu-prostate-cancer-best-researcher-award-2178/. With strong training from Jinan University (M.S. and Ph.D.) and postdoctoral stints at Ohio State University and the University of Maryland, Dr. Xu has made significant contributions to understanding the molecular mechanisms of cancer metastasis and therapy resistance. His interdisciplinary approach integrates molecular biology, proteomics, and translational oncology. With over 10 peer-reviewed high-impact publications and numerous collaborative studies, his research has directly impacted therapeutic developments in oncology. Dr. Xu also plays an active mentoring role in guiding junior scientists and has earned multiple academic scholarships and national honors, showcasing his consistent excellence in research and education.
Publication Profile:
Scopus
✅ Strengths for the Award:
-
Strong Research Output 📄
Dr. Xu has authored or co-authored 10+ peer-reviewed publications in high-impact journals such as Oncogene, Cancer Research, Journal of Pathology, and PNAS. His work spans from molecular mechanisms in cancer to translational applications, particularly in prostate and bladder cancers.
-
Expert in Molecular Oncology 🧬
His specialization in epigenetics, ubiquitin signaling, histone modification, and cancer metastasis showcases advanced, highly relevant research in oncology.
-
International Training 🌐
Dr. Xu completed postdoctoral research at Ohio State University Comprehensive Cancer Center and the University of Maryland, indicating significant global exposure and collaboration experience.
-
Technical Proficiency 🧪
Proficient in a wide range of molecular and cellular techniques, including SILAC proteomics, in vivo metastasis models, gene editing, and bioinformatics integration — making him a versatile and skilled experimental scientist.
-
Consistent Academic Excellence 🎓
Scholarships at the undergraduate, master’s, and Ph.D. levels affirm his long-standing academic merit and dedication to scientific advancement.
-
Collaborative and Interdisciplinary Research 🤝
Publications reflect multi-author, interdisciplinary studies, suggesting active collaboration across teams and institutions — a key indicator of leadership and teamwork in research.
⚠️ Areas for Improvement:
-
Independent PI Funding 🔍
While his contributions as co-author and corresponding author are impressive, it would further strengthen his candidacy to showcase grants as a principal investigator (PI) or lead large-scale funded research projects.
-
Conference Leadership and Awards 🗣️
Greater visibility through international keynote speeches, conference organization, or receiving international awards would elevate his profile on the global academic stage.
-
Translation to Clinical Practice 🧑⚕️
While his work is translational in nature, clinical application or trial participation would further highlight the real-world impact of his findings.
🎓 Education Background:
Dr. Song-Hui Xu received comprehensive academic training in biochemistry and molecular biology. He completed both his Master of Science (2009–2012) and Doctor of Philosophy (2013–2016) degrees at Jinan University in Guangzhou, China, a top-tier institution renowned for biomedical research. His graduate and doctoral research focused on cancer signaling pathways and the molecular basis of tumor metastasis, which laid a solid foundation for his future endeavors in cancer biology. His Ph.D. work was recognized through consistent academic scholarships, and it formed the core of his early publications in gastric cancer and signaling pathways. Dr. Xu’s educational journey has been marked by rigorous training, a deep interest in translational cancer biology, and an eagerness to explore mechanisms of cancer progression. His education also includes strong training in advanced experimental methodologies, including quantitative proteomics and genetic manipulation techniques, equipping him with cutting-edge skills for high-impact research.
🧪 Research & Professional Experience:
Dr. Xu has cultivated over a decade of research experience in molecular and cellular oncology. After earning his Ph.D., he joined Ohio State University Comprehensive Cancer Center (2016) and later the University of Maryland (2016–2020) as a postdoctoral fellow, focusing on prostate cancer signaling and epigenetic regulation. His work involved advanced techniques such as SILAC proteomics, cell migration assays, metastasis models, and ubiquitin signaling studies. Since returning to China, he has served as Associate Professor at Jiangxi Medical College, where he leads several projects on therapeutic resistance and cancer metastasis. He has collaborated with international researchers, contributing to impactful studies published in journals like Oncogene, Cancer Research, and J Pathol. His expertise lies in integrating molecular biology with translational oncology to develop novel therapeutic targets. Dr. Xu is also known for mentoring students, supervising lab operations, and contributing to multicenter studies in precision urology and machine learning-based cancer diagnostics.
🏅 Awards and Honors:
Dr. Song-Hui Xu has received multiple academic honors throughout his educational and professional journey. During his Ph.D. (2013–2016) and M.S. (2009–2012) programs at Jinan University, he was awarded academic scholarships for outstanding performance and research excellence. Earlier, from 2005 to 2009, he received the prestigious National Scholarship and university-level Student Scholarship, recognizing his academic consistency and leadership potential. His research excellence has also translated into international visibility, with his work cited in high-impact journals. While formal awards like “Best Researcher” are pending, his publication record and global collaborations reflect the hallmarks of a high-performing scientist. Dr. Xu’s contributions to oncology research, his role in mentoring, and his commitment to translational science position him as a worthy candidate for honors such as the “Best Researcher Award.” His trajectory reflects both depth in scientific knowledge and breadth in collaborative impact, with a strong drive to push the boundaries of cancer therapy.
🔬 Research Focus:
Dr. Xu’s research centers on the molecular mechanisms underlying cancer metastasis, therapy resistance, and epigenetic regulation in urological cancers, particularly prostate and bladder cancers. His investigations delve into the role of histone demethylases (e.g., JMJD1A), ubiquitin ligases (e.g., RNF41, STUB1), and the modulation of oncogenic pathways such as AR, c-Myc, and DNA damage repair. He leverages advanced technologies such as quantitative proteomics (SILAC), in vivo metastasis models, and CRISPR-based manipulation to explore these pathways. A notable aspect of his work is the translation of basic research findings into potential therapeutic interventions, including deubiquitinase inhibitors and androgen receptor modulators. Dr. Xu also engages in computational collaborations involving machine learning to predict clinical stages of prostate cancer. His interdisciplinary approach connects molecular biology with clinical relevance, helping identify new diagnostic markers and therapeutic targets. His consistent output and innovative methodology significantly contribute to advancing personalized oncology.
📚 Publications Top Notes:
1️⃣ 🧬 A noncanonical E3 ubiquitin ligase RNF41-mediated MYO1C stability promotes prostate cancer metastasis by inducing actin remodeling – Oncogene, 2024
2️⃣ 🧫 p300-mediated acetylation of histone demethylase JMJD1A prevents its degradation and enhances activity in prostate cancer – Cancer Res, 2020
3️⃣ 🔁 Targeting the KDM4B-AR-c-Myc axis promotes sensitivity to androgen therapy in advanced prostate cancer – J Pathol, 2020
4️⃣ 🚶♂️ ACK1 promotes gastric cancer EMT and metastasis via AKT-POU2F1-ECD signaling – J Pathol, 2015
5️⃣ 🔒 ECD promotes gastric cancer metastasis by blocking ZFP91-mediated hnRNP F degradation – Cell Death Dis, 2018
6️⃣ 🧬 USP3 stabilizes SMARCA5, enhancing DNA damage response and chemotherapy resistance in prostate cancer – Cell Death Dis, 2024
7️⃣ 🧪 Discovery and synthesis of novel phenoxyacetate ester Schiff base α-glucosidase inhibitors – Bioorg Chem, 2025
8️⃣ 🔬 JMJD1A enhances expression of DNA repair factors and radio-resistance in prostate cancer cells – Cell Death Dis, 2020
9️⃣ 🧠 Suicide mortality trends among prostate cancer survivors in the US, 1975–2019 – BMC Public Health, 2024
🔟 🧬 JMJD1A promotes AR-V7 alternative splicing in prostate cancer – PNAS, 2018
📌 Conclusion:
Dr. Song-Hui Xu is highly suitable for the Best Researcher Award based on his consistent scholarly output, impactful cancer research, international experience, and technical mastery. He demonstrates a strong blend of fundamental science with translational potential — essential traits of a modern biomedical researcher.
His publication record, molecular expertise, and collaborative reach place him in the top tier of emerging academic leaders. Strengthening his visibility through leadership roles and independent research grants would further cement his candidacy.